Cohen Independent Research Group publishes a report profiling Nutra Pharma

Oct 24 2009

Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that Cohen Independent Research Group has published a report profiling Nutra Pharma Corporation. The report, which was commissioned by Nutra Pharma, focuses on the company’s current drug development initiatives, including the company’s leading drug candidates for the treatment of Multiple Sclerosis (MS), HIV, Adrenomyeloneuropathy (AMN), and Rheumatoid Arthritis (RA) as well as the company’s recent launch of Cobroxin for the treatment of chronic pain.

A PDF of the research report can be accessed at: http://www.cohenresearch.com/reports/nphc_10-21-09.pdf